CH is typically defined by pathogenic driver mutations associated with hematological malignancies, most commonly in the epigenetic regulators DNMT3A, TET2, and ASXL1, which collectively account for 90% of CH cases (15–20). This evidence concerns the gene ASXL1 and cyclic hematopoiesis.